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INTRODUCTION 
Vitiligo is a common pigmentary skin disorder with an incidence of 1% 
worldwide.
[1]
 Widespread prejudices, ignorance, taboos, lack of scientific 
appraisal, and confusion of vitiligo with leprosy, all make it a social 
embarrassment for the patient,
[2]
 although it has no effect on life expectancy.
[3]
 
Vitiligo is considered as an idiopathic acquired depigmenting disorder 
characterized by depigmented macules of varying size and histologically by loss 
of functional melanocytes from the epidermis. This most commonly occurring 
pigmentary disorder involves complex interaction of environmental and genetic 
factors that ultimately leads to melanocyte destruction, resulting in depigmented 
lesions.
[4]
 
Its prevalence varies across different populations, being less frequent in 
Caucasians
[5]
 (0.38%), African
[6]
 (0.34%) and Chinese
[7]
 (0.0093%) than in 
Indians
[8],[9]
 (0.46–1.13%). The highest incidence has been reported in India 
followed by Mexico and Japan.
[10]
 Various theories such as genetic 
predisposition, neural and growth factor dysregulation, autoimmune 
phenomenon, autocytotoxic as well as inherent cellular metabolic defects leading 
to melanocyte apoptosis have been proposed.
[11]
  
Vitiligo has varied phenotypical expressions and several types of vitiligo 
are distinguished on clinical presentation. The natural course of disease is 
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gradual, unpredictable and difficult to control. Sometimes the disease persists for 
a long time in a stable status.
[12]
  
Various medical and surgical modalities of treatment are available for 
vitiligo which includes topical corticosteroids, vitamin D3 analogs, 
immunomodulators and other modalities like PUVA, NBUVB, cultured 
melanocyte suspensions, skin grafting, camouflage and psychological therapy.
[13]
 
Despite several therapeutic modalities, the treatment of vitiligo still 
remains unsatisfactory. Studies have shown that topical immunomodulators 
(tacrolimus, pimecrolimus) are considered as safe and effective agents for long-
term use in vitiligo as they do not cause skin atrophy which is associated with 
prolonged use of topical corticosteroids. Tacrolimus acts by inhibiting the 
activation and maturation of T cells by means of blocking the action of 
calcineurin and interleukin IL2, IL4, IL5 transcription. The positive effects of 
this drug in vitiligo have been demonstrated in vitro studies which showed 
increased proliferation of melanocytes and melonoblasts in epidermal cell 
cultures.
[14]
 
NB-UVB is used widely in the treatment of vitiligo because of its safety 
and efficacy. Significant repigmentation in either generalized or segmental 
vitiligo with NBUVB have been shown in recent reports. It acts by inhibiting the 
induction and secretion of cytokines, and stimulating inactive melanocytes in the 
outer root sheath of hair follicles to proliferate and migrate into vitiligo lesions. 
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There are only few studies to compare the efficacy and tolerability of 
NBUVB therapy & tacrolimus in the treatment of vitiligo. More number of 
studies to compare the same is required. Hence this prospective study is 
conducted to present a relatively new mode of treatment which may be beneficial 
to the patients of vitiligo. It may also cause quick symptomatic improvement, 
thus decreasing the psychological distress of patients due to cosmetic 
disfigurement caused by vitiligo. 
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REVIEW OF LITERATURE 
 
HISTORICAL ASPECTS 
 Vitiligo was observed very early in history, and one of the earliest terms, 
Switra, came from the Rig Veda meaning “spreading whiteness”. In 1550 BC 
Ebers Papyrus mentioned two types of skin diseases characterized by changes in 
the colour of the skin. One disorder could be interpreted as leprosy as „thou shalt 
not do anything to it‟. The other characterized by a lack of pigmentation, 
probably vitiligo.
[15]
  
 Vitiligo was known by various names such as „Bars‟, „Bahak‟, „Sufaid‟, 
„Phulbahari‟, „Kilas‟, „Palida‟, „Sweta Kushta‟, „Dhawal Kushta‟.[10] 
 In a translation of the Atharv Veda in 1905 „kilas‟ was equated with the 
term „vitiligo‟. The term „kilas‟ was derived from the sanskrit word „ku‟ meaning 
„white‟ in the sense of „casting away‟. A collection of Shinto prayers from the far 
east known as Makatominoharai in l200 BC reported on „shira bitu‟ meaning 
„white man‟, and in some incidences it may also be interpreted as vitiligo. Much 
emphasis on „white spots‟ were  found in the Greek literature, Herodotus, a 
Greek historian, wrote in his book CIio that foreigners who suffered from such 
lesions, must have „sinned against the sun‟.[16] 
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 In 200 BC, the Indian book Manu Smriti described „Sweta Kushtha‟ 
meaning „white disease‟, skin lesions which probably were vitiligo.[17] 
Histopathological features of vitiligo were first described by Moritz Kaposi.
[17]
 In 
Tamil Nadu, vitiligo was described as “ven Kushtha” from olden days. 
 Years later vitiligo was derived from Latin word „vitelius‟ meaning vale 
i.e., pale pink flesh of calf, while others believed that it was originated from 
Latin word „vitium‟ meaning blemish. Finally Celsus was the first to use the 
word vitiligo in his classic Latin book De Medicina in the first century which has 
become established since then.
[16]
 
EPIDEMIOLOGY 
 Vitiligo is a common disorder affecting all races and geographic areas 
with a prevalence of 0.5% to 2% worldwide. The prevalence varies across 
populations, 0.38% in Caucasians, 0.34% in African Caribbean and 0.0093% in 
Chinese, 0.46–1.13% in Indians.[8,9] 
 
Vitiligo may manifest at any time in an individual's lifespan with an 
average age at onset of 20 years.
[18]
 Men and women are equally affected, but 
some studies indicates a slight higher prevalence of cases among females,
[10]
 
possibly due to greater psychosocial consequences caused by this skin condition; 
however, this  is not considered statistically significant because some studies 
show similar rates for both genders.
[19]
 A minority of cases (10% to 15%) in 
adults present in segmental form. In children, the segmental variant is more 
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prevalent. Childhood vitiligo has been associated with atopic diathesis, family 
history of vitiligo and autoimmunity.
[20]
 Worldwide studies also indicates that 
there is genetic heterogeneity in different ethnic groups in terms of their 
susceptibility to develop vitiligo.
 
 Vitiligo affects people with mostly skintypes III and IV. It occurs more 
frequently in sun exposed areas and in darker skin types.
[10]
 Diet deficient in 
proteins and cuprominerals is thought to be contributory to vitiligo.
[21]
 
AETIOPATHOGENESIS 
 Vitiligo is a multifactorial polygenic disorder that causes melanocyte 
destruction in skin and mucous membrane.
[22,23]
 The exact etiology of vitiligo is 
uncertain. Genetic factors, immunological, self destructive mechanisms, neural 
and intrinsic mechanisms play role in pathogenesis.     
Genetic inheritance: 
 Inheritance was considered to be autosomal dominant having variable 
expression and imperfect penetrance.
[24,25,26]
 The possibility of autosomal 
recessive or polygenic inheritance with its somatic expression decided by 
precipitating factors has been suggested. The familial incidence is between               
20 – 30%. [24] 
 The genetic associations of vitiligo and alleles of major histocompatibility 
complex (MHC) loci are strong in patients (and families) where vitiligo is 
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associated with other autoimmune disease. Various genetic susceptibility locuses 
for vitiligo are catalase gene (Cat),
[27]
 chromosome 2 locus (Vit-1 gene),
[28]
 
chromosome 1 locus (AIS1),
[29]
 specific HLA haplotypes
[30]
 and a mutation in 
GTP-cyclohydrolase the rate-limiting enzyme for 6-BH4 synthesis.
[31]
 Genome-
wide linkage analyses in recent years identified multiple linkages to vitiligo
[32]
 on 
chromosome 1p (AIS1), 7p (AIS2), 8p (AIS3), and 17p (NALP1/SLEV1). 
Autoimmune susceptibility locus (AIS): AIS1 and AIS2 were identified from 
families with vitiligo-related autoimmune disorders, while AIS3 was primarily 
identified from nonautoimmunity-associated families. Mutations in NALP1 
which encodes a protein called NACHT that regulates the activation of caspases 
were found in patients with associated autoimmune features. Eventually, despite 
the fact that vitiligo is equally widespread in different areas of the world; 
different ethnic roots may express genetic heterogeneity with little or no overlap 
between susceptibility loci in different populations.
[33]
 
THEORIES ON THE PATHOGENESIS 
 Besides genetic predilection, diverse epigenetic factors play a role in 
etiopathogenesis.  Theories on the pathogenesis include autoimmune theory, 
neural theory, intrinsic and self destructive theory, impaired redox status theory 
and melanocytorrhagy. 
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Autoimmune theory: 
 This theory involves changes in cellular and humoral immunity leading to 
melanocyte destruction and it is accepted as the common cause of vitiligo. 
Thyroid disorders, particularly Hashimoto‟s thyroiditis and Graves‟ disease, 
endocrinopathies, such as Addison‟s disease and diabetes mellitus; autoimmune 
diseases like alopecia areata , pernicious anemia,  psoriasis, autoimmune 
polyglandular syndrome and inflammatory bowel disease can occur in 
association with vitiligo.
[34]
 
 Evidence in favour of an autoimmune pathogenesis includes the presence 
of organ specific antibodies in patients with vitiligo.
[35]
 
 Autoreactive CD8
+ 
T cells causes melanocyte destruction and this is 
evidenced by demonstration of activated CD8
+ 
T cells in perilesional skin. 
Further, peripheral blood examination shows melanocyte-specific T cells in 
patients with associated auto immune disease.
[36, 37]
 
Neural theory: 
 Peripheral nerve endings may secrete a substance that is cytotoxic to 
melanocytes causing the destruction. This is shown by evidence that segmental 
vitiligo occurs in a precise dermatomal pattern indicating the skin is feasibly only 
being affected by the nerves of that particular dermatome. Moreover, vitiligo 
occurs with certain neurological disorders such as encephalitis and trauma that 
causes peripheral nerve damage.
[38]
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 Nerve endings in depigmented areas produce abnormal neuropeptides and 
nerve growth factors that are toxic to melanocytes. Depigmented areas shows 
abnormal autonomic functions such as increased adrenergic tone, norepinephrine 
and an increased concentration of catecholamines. Administration of nialamide, 
an oral MAO inhibitor to suppress metabolism of catecholamines at sympathetic 
nerve endings induces repigmentation in segmental lesions.
[39]
 
 In addition, patients with vitiligo demonstrate increased urinary excretion 
of neurometabolites such as homovanillic acid and vanilmandelic acid.
[22] 
These 
evidences put forward that neurotransmitter release may possibly directly or 
indirectly relate to melanocyte destruction and depigmentation. 
A.B. Lerner’s Self Destructive Theory: 
 Some of the intracellular premelanogenesis metabolites such as dopa, 
dopachrome are toxic to melanocytes. Elimination of toxic melanin precursors 
does not possibly occur, eventually causing death of melanocytes or that usual 
progression of melanosome degradation proceeds unabated to cause melanocyte 
death.
[40]
 
 Evidences in favour are phenolic compounds have the potential to produce 
vitiligenous lesions. Some hydroquinone derivatives are related to these 
intracellular metabolites which causes leukoderma investigational. 
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Biochemical theory – impaired redox status theory: 
 Oxidative stress hypothesis suggests that imbalanced redox (reduction-
oxidation) state of the vitiliginous skin results in the dramatic production of 
reactive oxygen species (ROS), as H2O2. ROS oxidizes components of the cell 
leading to melanocytes destruction and creating the depigmented macules.
[41]
 
High level of catecholamine discharge in epidermis could lead to ischemia and 
subsequent overproduction of reactive oxygen species. Another cellular pathway 
affected by accumulating H2O2 involves tetrahydrobiopterin increase which 
inhibits tyrosinase activity and extremely cytotoxic to melanocytes. 
Intrinsic theory: 
 Melanocytes in vitiligo have an intrinsic defect leading to their death. 
They demonstrate different abnormalities, including abnormal rough 
endoplasmic reticulum or deficiency of unidentified melanocyte growth factors 
such as basic fibroblast growth factor (bFGF) and decrease in the number of 
melanocytes expressing the c-kit receptor in lesional skin.
[42,43]
  
 Melanocytes require a constant keratinocyte-derived c-Kit stimulation for 
their maintenance,
[44]
 thus weak expression of keratinocyte-derived factors, as 
stem cell factor (SCF), may lead to passive melanocyte death.  
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Melanocytorrhagy - A New Integrated Theory: 
 Vitiligo is considered as a primary melanocytorrhagy disorder with an 
altered melanocyte responses to trauma, friction and possibly other types of 
stressors, catecholamines, ROS and autoimmune elements inducing the 
detachment and subsequent transepidermal loss.
[45]
 Dendrites of melanocytes 
helps in melanosomes transfer to the surrounding keratinocytes and also 
adherence to basal membrane. Addition of H2O2 in established cultures of normal 
melanocytes induces loss of dendrites and melanocyte detachment. The increased 
release of catecholamines might be an aggravating factor of Non Segmental 
Vitiligo (NSV). Dendrites are lost in response to reactive oxygen species or by 
increased release of catecholamines which exaggerates transepidermal loss, and 
eventually to their detachment by mechanical or chemical injury.
[46]
 
Convergence theory: 
 Following genetic studies, it was proposed that vitiligo has a multi-faceted 
etiology and involves combined mechanisms of the above mentioned theories 
and genetics. This theory states that genetic factors have a role in inducing 
vitiligo along with other elements such as stress, infection, autoimmunity, 
accumulation of toxic compounds, mutations and impaired melanocyte 
proliferation.
[47]
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CLINICAL FEATURES 
 A typical lesion is a well-defined depigmented macule often showing 
variable number of depigmented hair. 
 The onset of the disease is usually insidious and progressive and the 
course of disease is virtually unpredictable. The disorder affects both sexes and 
all races equally. It is usually asymptomatic, but some may have itching or 
burning sensation preceding or accompanying the onset of lesions. Most people 
with vitiligo are otherwise healthy and have normal skin texture and sensation.
[48]
 
The initial lesion may be depigmented macules or patches varying widely in size, 
shape, number and location.
[49]
 The lesions may or may not be symmetrical and 
can spread over entire body. 
 Although any part of the body may be affected by vitiligo, depigmentation 
usually first develops on sunexposed areas such as hands,  feet , arms, face and 
lips followed by body folds(armpits, groin), nipple and genitalia. Involvement of 
pretibial region, palms and soles are quite common in India.
 [50,51] 
 Mucous membrane involvement is frequently observed in settings of 
generalized vitiligo. In addition vitiligo patches show depigmented hair 
(Leukotrichia). Presence of leukotrichia indicates poor prognosis with regard to 
pigmentation.  
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Course of the disease 
 Vitiligo is a slow and progressive disease with remissions and 
exacerbations correlating with triggering events. The natural course of vitiligo is 
difficult to predict.
[48] 
 Sometimes the patches stop progressing without treatment. In others, 
pigment loss can involve most of the surface of skin. Extension of vitiligo can 
occur over a few months, then it stabilizes. Spontaneous repigmentation may 
occur in few patches while others show extension. Cycles of pigment loss 
followed by periods of stability may continue indefinitely. Sometimes lesions of 
vitiligo begin to occur around a pigmented nevus and then spread to distant 
regions. 
 Koebner‟s phenomenon can be noted in both segmental and nonsegmental 
vitiligo. Presence of koebnerisation is indicative of disease activity.
[52]
 Very 
sudden onset, rapid spread of lesion has been noted in emotional trauma and 
repression. Such cases are referred to as valeceo type of vitiligo. 
CLASSIFICATION 
1) Classification based on extent of involvement, number and distribution of 
depigmented patches.
 [53,54]
 
a) Localised (focal, segmental and mucosal types) 
b) Generalized (vitiligo vulgaris, acrofacial, mixed and universalis) 
14 
 
Localised vitiligo 
i. Focal vitiligo: 
Characterized by an isolated macule or a few scattered macules in one area. 
ii. Segmental vitiligo: 
 Segmental vitiligo manifest as depigmented macules and patches 
occurring in a dermatomal or quasidermatomal pattern and is most often 
unilateral. It has an earlier onset, spreads much more rapidly than NSV and 
stabilizes within a year or two of its onset. This type of vitiligo occurs more 
commonly in children. More than half of the patients have patches of white hair 
(poliosis). Usually it is not associated with other autoimmune diseases as that of 
generalized vitiligo. 
iii. Mucosal vitiligo: 
 Depigmentation affecting mucous membrane alone. 
Generalized vitiligo 
i.  Vitiligo vulgaris:  
 It is the most common form of vitiligo with generalized distribution. It 
usually involves the extensor surface of hands, feet, legs, axilla and face in a 
symmetrical pattern.  
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ii. Acrofacial vitiligo: 
 Depigmentation occurs predominantly on acral parts of limbs (hands, feet, 
finger, toes, palms and soles) and face (periorificial areas) 
iii. Mixed type vitiligo: 
 Acrofacial and vitiligo vulgaris occurring in combination or vulgaris and 
segmental vitiligo occurring in same patient has been noted. 
iv. Vitiligo universalis:  
 Depigmentation is so widespread that it involves entire or nearly entire body 
surface area. 
Classification based on progression of disease
 [55]
 
1. Stable vitiligo: Vitiligo that are stationary and no new lesions. 
2. Unstable vitiligo: Vitiligo that have developing new lesions, and 
increasing old lesions with ill-defined borders. 
Indian Classification 
1. Segmented vitiligo (Vitiligo zosteriformis) 
2. Non-segmental vitiligo (Focal vitiligo, vitiligo vulgaris, acrofacial vitiligo, 
universal vitiligo, mucosal vitiligo). 
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Morphological variants
 [56]
 
1) Trichrome vitiligo refers to three shades of color – brown, tan and white. 
An intermediate zone of hypochromia is located between depigmented 
patch and peripheral normal skin. 
2) Quadrichrome vitiligo refers to presence of marginal hyperpigmentation in 
addition to trichrome vitiligo at the sites of perifollicular repigmentation. 
3) Pentachrome vitiligo has five shades of colour – white, tan, brown, blue-
grey hyerpigmentation and normal skin. 
4) Blue vitiligo refers to vitiligo macules occurring in post inflammatory 
hyperpigmentation sites. 
5) Marginal inflammatory vitiligo – have a red raised border associated with 
mild pruritus.  
6) Confetti macules are typical 1 to 2mm diameter depigmented macules 
occurring randomly or at perifollicular region. 
Associations of vitiligo 
Cutaneous associations:  
 Frequently reported associations are premature greying of hair,
[57]
 poliosis, 
halonevus, alopecia areata and lichenplanus.
 [58]
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 Autoimmune diseases associated include morphea, lichen sclerosis, lupus 
erythematosus and Hashimoto‟s thyroiditis.[59] 
 Other disorders, occasionally that have been reported with vitiligo are 
dermatitis herpetiformis,
[60]
 psoriasis, chronic utricaria, Naevus depigmentosus, 
chronic actinic dermatitis and malignant melanoma.
[61]
  
Systemic associations: 
 Diabetes mellitus, hypo and hyperthyroidism, Addison,s disease, 
pernicious anemia,
[62]
 ulcerative colitis, myasthenia gravis, thymoma, 
autoimmune polyendocrinopathy candidiasis ectodermal dystrophy, and human 
immunodeficiency virus 
[63]
 are associated with vitiligo. 
Syndromes associated with vitiligo
[64,65]
 
1) Alezzandrini syndrome: Rare syndrome characterized by unilateral 
facial vitiligo, poliosis and unilateral impairment of vision. 
2) Vogt-koyanagi harada syndrome: Vitiligo associated with bilateral 
diffuse granulomatous uveitis, poliosis, alopecia, central nervous system 
involvement and deafness. 
HISTOPATHOLOGY 
 Although the diagnosis of vitiligo is generally made on the basis of 
clinical findings, biopsy is helpful for differentiating vitiligo from other 
hypopigmentary disorders. 
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 Microscopic examination of a well-established vitiligo lesions shows 
complete absence of melanocyte in association with a total loss of epidermal 
pigmentation. Early evolving lesions show few DOPA positive melanocytes and 
some melanin granules at the basal layer. In outer borders of patches of vitiligo, 
melanocytes are often prominent and show long dendritic processes filled with 
melanin granules. Superficial perivascular and perifollicular lymphocytic 
infiltrates along with focal basal layer vacuolar changes may be observed at the 
margin of vitiliginous lesions, consistent with a cell-mediated process destroying 
melanocytes. Degenerative changes have been documented in keratinocytes and 
melanocytes in both the border lesions and adjacent skin. Loss of pigment and 
melanocytes in the epidermis is highlighted by Fontana – Masson staining and 
immunohistochemistry testing.
[66,67]
  
VITILIGO THERAPY 
 From time immemorial, many varied indigenous folk medicines have been 
used in different countries for the treatment of vitiligo. An oily extract of the 
seeds of Psoralia corylifolia, Chinese herb and the dried powdered preparations 
made from fruits of Ammi majus, an Egyptian herb were among the preparations 
which dominated the field. These herbal products contain photosensitizing 
furocoumarin chemicals which helps in pigmentation. 
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 Modern treatments can be divided into the following categories: 
1. General aspects 
2. Medical therapy 
i. Topical  
    Corticosteroids 
 Immunomodulators 
 Vitamin D3 analogs 
 Pseudocatalase 
 Basic fibroblast growth factor 
 Placental extracts 
ii.  Systemic 
 Corticosteroids 
 Cyclophosphamide 
 Azathioprine 
 Levamisole 
3. Phototherapy 
 Topical PUVA 
 NB-UVB 
 Systemic PUVA 
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 Phenylalanine with UVA 
 Khellin with UVA exposure 
 Excimer laser 
4. Surgical therapy 
5. Adjuvant therapy 
 Selection of a specific therapy depends on effectiveness supported by 
evidence based information and according to dermatologist experience since 
diverse treatments may offer comparable results. When therapeutic failures to 
first line treatments occur, alternate therapy should be tried. 
GENERAL ASPECTS 
 Nature of the disease, its course and prognosis should be explained to the 
patient. They should have a balanced nutritious diet enriched with adequate 
proteins, vitamins B-complex and E, and minerals such as copper, zinc and iron. 
They need to be instructed regarding avoidance of physical, chemical and 
emotional trauma as far as possible. Avoidance of substances containing phenolic 
compounds, rubber goods and contact exposure to other chemical agents known 
to be detrimental to melanization is advisable. 
MEDICAL THERAPY 
 Depigmentation in vitiligo should be initially treated with medical 
therapy. Medical therapy includes  
21 
 
TOPICAL  
Corticosteroids: 
 Topical corticosteroids have virtually become the first line of treatment for 
patients with a few localized lesions. Potent fluorinated corticosteroids yield 
results when used for a period of 2 to 4 months, but side effects like atrophy, 
telangiectasia, striae and percutaneous absorption resulting in chronic adrenal 
insufficiency may develop during which case treatment needs to be interrupted
 
[68]
. Other side effects like increased intraocular pressure and glaucoma call for 
extra caution. To avoid these undesirable effects, interrupted topical therapy 
which includes application twice or once daily for 2 months followed by a 
treatment-free period of 2 weeks in cyclic order can be done. 
Vitamin D3 analogs:  
 Topical calcipotriol and tacalcitol causes specific T-cell activation and 
inhibition of the expression of various proinflammatory cytokines that encode 
tumor necrosis factor-alpha and interferon gamma. These vitamin D3 compounds 
influence melanocyte maturation and differentiation, in addition to up-regulating 
melanogenesis through pathways that are activated by specific ligand receptors 
(e.g., endothelin receptor and c-kit).
 [69] 
Pseudocatalase: 
 Pseudocatalase has been used to reconstitute deficient activity of catalase 
in vitiligo epidermis, degrading excessive H2O2 and allowing recovery of enzyme 
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activities in vitiligo skin. Pseudocatalase monotherapy or combination with NB-
UVB has been claimed to produce repigmentation and prevention of disease 
progression in vitiligo patients.
[70]
 
Basic fibroblast growth factor: 
 Melanocyte chemokinetic movement was induced by bFGF, stem-cell 
factor, endothelin-1 and leukotriene C4. These factors induce proliferation and 
migration of melanocytes from outer root sheath of hair follicle into the 
depigmented epidermis stimulating vitiligo repigmentation.
[71] 
Placental Extracts: 
 Human placental extracts can be used topically in the treatment of vitiligo. 
It is usually applied on vitiligo skin  twice or thrice daily along with UV 
exposure. It has a mitogenic effect on the skin melanocyte and stimulating effect 
on the course of melanogenesis in surviving melanocytes. Glycosphingolipids 
exist in placental extract induces adhesion, spread and motility of 
melanocytes.
[72]
 
SYSTEMIC 
Corticosteroids: 
 Systemic corticosteroid therapy has been administered in pulse form in 
order to reduce the side effects. Oral minipulse (OMP) therapy involves 
administration of cyclical pulsed oral betamethasone as a single morning dose of 
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0.1 mg/kg body weight on two successive days in a week for 12 weeks and 
subsequently decreasing the dosage by 1mg/month for the following 3 months.
[73]
 
Cyclophosphamide: 
 Assuming an autoimmune cause for vitiligo, this drug has been tried in the 
dosage of 50 mg twice a day orally. Along with oral corticosteroids it has been 
reported to be beneficial in preventing the disease activity and in repigmenting 
vitiligo lesions. 
Azathioprine: 
 Azathioprine can be used for the treatment of vitiligo alone or along with 
other modalities such as oral PUVA or UVB. 
Levamisole: 
 It is used in the dose of 150 mg on two consecutive days in a week in 
adults. 
PHOTOTHERAPY 
 Phototherapy remains the main stay of treatment in vitiligo even today. 
The mechanism of action of PUVA therapy includes the following 
1. Stimulates melanogenesis by photoconjucation of psoralens to DNA in 
melanocytes, mitosis and subsequent proliferation of melanocytes. 
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2. Increase  in tyrosinase activity  
3. Increased formation and melanization of melanosomes. 
4. Increased transfer of melanosomes to keratinocytes.  
Topical PUVA: 
 Topical PUVA is often indicated in patients with limited disease, usually 
less than 20% of body surface area. Usually 0.1% psoralen is applied over 
vitiligo patch weekly followed 2-3 hours later by solar UVA radiation for 30 to 
60 seconds. Exposure can be increased by 30 seconds per session and the 
frequency of exposure can be increased twice weekly until the patch becomes 
slightly erythematous. 
 After treatment the area should be washed and photoprotected with 
sunscreen. Further exposure to sunlight for at least 12 hours should be avoided to 
prevent phototoxicity.  
 Side effects of topical PUVA therapy includes blistering, erythema and 
dark repigmentation.
[74]
 
Systemic PUVA: 
 Systemic PUVA involves use of oral psoralens combined with UVA 
exposure. Three psoralens are used: 8 methoxypsoralen or 8-MOP, Bergaptan or 
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5-MOP and Trioxsalen or 4, 5, 8 trimethyl psoralen. Of these, 8 methoxypsoralen 
is most commonly used.  
 In oral PUVA, 8-MOP is administered orally 0.6–0.8 mg/kg body weight 
1–3 hours before exposure, depending on the absorption characteristics of the 
particular drug. For 5-MOP, the usual dosage is 1.2 to 1.8-mg/kg body weight. 
The first therapeutic UVA dose is determined by calculating the minimal 
phototoxicity dose (MPD) which is done by phototesting.
[75]
 The MPD is defined 
as the minimal dose of UVA that produces a barely perceptible, but well-defined, 
erythema when template areas of the skin are exposed to increasing doses of 
UVA. Erythema readings are performed 72 hours after testing, at which time the 
psoralen phototoxicity reaction usually reaches its peak. 
 When phototesting is not feasible, the initial dose may be evaluated with 
respect to the type of skin. The treatment is generally commenced with an initial 
dose of 1–2 J/cm2; 2–3 sittings per week  and the dose may successively be 
increased by 0.5 J/cm
2
 if the previous dose induces no or negligible erythema. 
 Therapy usually needs to be continued for 9–19 months. It has been 
estimated that about 150–300 exposures may be needed for acceptable 
improvement. Pigmentation reappears first usually perifollicularly and then 
slowly extend to become confluent. Concurrently it also occurs at the margins. 
Repigmentation occurs more readily on the face, neck, hairy and muscular 
regions than on the dorsum of hands, elbows, and ankles.
[76]
 Side effects of this 
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therapy include nausea, vomiting, epigastric discomfort, pruritus, erythema, 
blistering reactions, nervousness, insomnia and photocarcinogenesis. 
Phenylalanine with UVA exposure:  
 Phenylalanine has been used orally and topically with UVA exposure. 
Topical 10% L-phenylalanine cream applied over vitiligo patches 20 minutes 
before UVA exposure gives better results. Orally 5% aqueous L phenylalanine 
solution is administered 1 hour prior to irradiation. UVA exposure is usually 
done twice a week for 6 months. The most common areas of repigmentation are 
the arms, legs, knees and eyelids. Usually there are no side effects of this 
therapy.
[77]
 
Khellin with UVA exposure: 
 Khellin is a furanochrome isolated from the seeds of plant Ammi visnaga 
of eastern Mediterranean area. It has been found to be as effective a 
photosensitizer as psoralen and its free from phototoxic effects.
[78]
 
Excimer laser (308 nm):
[79]
 
 Excimer laser, which produces monochromatic rays at 308 nm is used to 
treat limited, stable patches of vitiligo. This new treatment is an efficacious, safe, 
and well-tolerated treatment for vitiligo when limited to less than 30% of the 
body surface area. Localized lesions of vitiligo are treated twice weekly for an 
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average of 24-48 sessions. Initial pigmentation is seen at 4-8 weeks. It acts 
through immunomodulation by affecting the T cells. 
SURGICAL THERAPY 
 Patients who have small areas of vitiligo with stable activity for at least 2 
years and absence of new koebnerization, and unresponsive to other treatment 
modalities are suitable for surgical therapies 
Five basic methods for repigmentation surgery have been described. 
 Punch minigrafting 
 Suction epidermal grafting 
 Thin dermoepidermal grafts 
 Noncultured epidermal suspensions  
 Cultured epidermis with melanocytes or cultured melanocyte               
 suspensions.
[80]
 
ADJUVANT THERAPY 
 Depigmentation: The form of treatment when vitiligo is extensive i.e. 
vitiligo universalis. It involves fading the rest of the skin on the body so that it 
matches with the already white areas. For this, permanent melanocytotoxic 
agents such as 20% monobenzyl ether of hydroquinone is used. 
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 Sunscreens: Sunburn and long term photodamage are common in people 
who have vitiligo. Prevention of sun-induced darkening of the surrounding 
normal skin can be achieved by using broad spectrum high protection factor 
sunscreens (SPF15-30) to provide protection from both UVB and UVA light. 
 Cosmetics: Using camouflage, affected areas can be “covered”. Patients 
having minimal disease or segmental disease can be practically treated. In India, 
there are many brands of dyes like Dermacolor (Kryolan) and Dermablend 
(L‟Oreal)  available. 
TOPICAL CALCINEURIN INHIBITORS AND PHOTOTHERAPY 
 Narrow-band UVB phototherapy and topical tacrolimus are among the 
most innovative approaches to vitiligo. 
Topical Tacrolimus 
 One of the emerging topical drug used in vitiligo is topical calcineurin 
inhibitors. Tacrolimus also called FK506 or fujimycin is a 23 membered 
macrolide lactone that was discovered in 1987 from the fermentation broth of a 
Japanese soil sample that contained bacterium Streptomyces tsukubaensis. It was 
among the first macrolide immunosuppressants discovered, preceded by the 
discovery of Rapamycin (Sirolimus). It was isolated from soil bacterium 
streptomyces tsukubaensis. The name Tacrolimus was derived from Tsukuba 
macrolide immunosuppressant.
[14] 
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Mode of action 
 Tacrolimus is a macrolide calcineurin inhibitor. The biological activity of 
tacrolimus takes effect after binding to the cytosolic 12kD macrophilin FK506 
binding protein. The tacrolimus/FK-binding protein complex inhibits calcineurin 
mediated phosphorylation of transcription factor NFAT (Nuclear factor of 
activated T cells). 
 This inhibition prevents signal transition pathways from occurring which 
ultimately halts the transcription of  cytokines IL2, IL3, IL4, IL5, IL8, tumour 
necrosis factor α and interferonγ.  
 It also causes down regulation of FCeR1 receptors on surface of 
langerhan‟s cells and inhibition of CD4 and CD8 lymphocyte migration. 
 Other actions of tacrolimus include impairment of synthesis of 
prostaglandin-D2 as well as dose dependent decrease of histamine release from 
skin IgE-activated mast cells.
[14]
 
Topical tacrolimus with NB-UVB 
 Topical tacrolimus induces follicular repigmentation by stimulating the 
proliferation of inactive melanocytes from outer root sheath of hair follicle as 
well as melanoblast differentiation and growth.  
 Topical tacrolimus induces tyrosinase enzyme activity which eventually 
leads to melanin biosynthesis, activity and expression. In vitro studies show, at 
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molecular level, the concentration of stemcell factor in keratinocyte supernatant 
increases in a dose dependent manner. 
 The suppression of proinflammatory cytokines via tacrolimus facilitates 
the stimulatory effects of UVB light on the repigmentation of vitiliginous skin. 
 Additionally topical tacrolimus promotes favourable environment that 
fosters the proliferation of melanocytes/melanoblast through interaction with 
keratinocytes in sun exposed vitiliginous skin.
[81]
 
Pharmacokinetics  
 The absolute bioavailability of topical tacrolimus is unknown. The peak 
blood concentrations after single or multiple doses of 0.1% tacrolimus ointment 
where in the range of 5-20 ng/ml. Systemic absorption with topical tacrolimus is 
minimal.
 
Indications 
 FDA approved indication of topical tacrolimus includes atopic dermatitis. 
Other indications in skin diseases includes vitiligo, psoriasis, oral lichenplanus, 
pemphigus vulgaris, bullous pemphigoid, alopecia areata, lichen sclerosus et 
atrophicus, contact dermatitis and graft versus host disease.
[14] 
Contraindications 
 Absolute:  Hypersensitivity to topical tacrolimus 
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 Relative:  children < 2 years of age, active skin infection at the site to 
   be treated.
[14] 
Preparations and formulations 
 Tacrolimus: 0.03% and 0.1% ointment. 
 It has been approved for use in children aged 2 to 14 years at 0.03% 
ointment concentration. While in adults 0.1% ointment concentration has been 
approved for use. 
Advantage of topical tacrolimus 
 Topical tacrolimus offers many advantages over topical corticosteroids in 
vitiligo as it does not cause atrophy, telangiectasia, or adverse ocular effects of 
topical corticosteroids, which has limited applications to the face and 
intertriginous areas. 
Side effects 
 Skin burning sensation, pruritus, hyperesthesia, stinging, soreness.
[81]
 
Narrowband-UVB 
 Phototherapy is one of the most innovative approach in treatment of 
vitiligo.   
History 
 The first reported use of „phototherapy‟ dates back 1400 BC in India. In 
the past vitiligo patients were treated with certain plant extracts, Ammi majus 
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and Psoralea corylifolia and then exposed to the sun. The modern day 
phototherapy came into existence in 1903 when Niels Finsen used UV irradiation 
for treating lupus vulgaris.
[82]
 
 In 1978 broadband UVB irradiation cabins were introduced by 
Wiskemann in the treatment of psoriasis and pruitus. In 1988, narrow-band UVB 
(NB-UVB) phototherapy was introduced for the treatment of psoriasis by Van 
Weelden et al and Green et al.  
 Psoralen and ultraviolet A (PUVA) introduced in 1948, remained the 
mainstay of vitiligo management, until Westerhof and Nieweboer‑Krobotova, 
introduced narrowband ultraviolet B (NBUVB) in the treatment of vitiligo in 
1997. NBUVB has effectively replaced PUVA therapy due to its superior 
efficacy and better side‑effect profile.[83] 
Phototherapy unit 
 Ultraviolet radiation has become an essential part of dermatological 
therapy in management of skin diseases. Many studies have revealed the use of 
UV radiation in the treatment of chronic inflammatory skin diseases. 
 In the past, broad-band UVB (290-320 nm), long wave UVA (320-400 
nm) or combined regimens were used in treatment of skin diseases. Newer 
phototherapeutic modalities such as narrowband UVB (TL-01), long-wave UVA 
(UVA1), bath water delivery of 8-MOP followed by UVA (bath-PUVA), UVA/B 
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extracorporeal photopheresis (ECP) and photodynamic therapy have been 
developed in recent years. 
 NB UVB phototherapy cabins have fluorescent bulbs (Phillips model 
TL‑01). It emits UVB radiation in the range of 310–315 nm. When compared 
with the older broadband UVB source, NBUVB phototherapy cabins have 
relatively narrow spectrum of emission with peak at 311 nm. It has 5-6 times 
greater emission of the longer UVB wavelengths.
[84]
 
 A wide variety of narrow-band UVB equipments are available which 
includes the following:
[84] 
1. Whole body cabins 
2. Whole body panels 
3. Small panel irradiators 
4. Hand and foot unit 
5. NBUVB comb 
6. Home phototherapy units (e.g., SS‑01UV phototherapy instrument)  
 NBUVB cabins either incorporate fluorescent bulbs TL‑01 alone or 
combined with UVA tubes. Home based phototherapy units,  which was recently 
introduced is SS‑01UV phototherapy instrument (Shanghai Sigma High‑tech 
Co. Ltd, Shanghai, China).The equipment has two Philips TL‑9 W/01 lamps and 
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it delivers NB‑UVB rays of wavelength spectrum 310–315 nm, with a maximum 
of  311 nm and radiant intensity of approximately 10mW/cm2, over a 9 × 7 cm 
area. It is used mainly in the management of localized vitiligo lesions.
[84]
 
Mechanism of action of narrowband-UVB 
  NB-UVB has relatively more suppressive effect on systemic immune 
response than broadband UVB. NB-UVB radiation is absorbed by DNA and 
urocanic acid in the skin and it alters antigen presenting cell activity. NB-UVB 
phototherapy lowers peripheral natural killer cell activity, lymphocyte 
proliferation and immune regulatory cytokine production by both Th1 (IL-2, 
IFN-γ) and Th2  (IL-10) T-cell populations. In addition NBUVB is 5-10 times 
less potent in causing erythema, edema and sunburn than broad band UVB. 
 
 Narrowband ultraviolet B exerts its effects in vitiligo in a two‑step 
process occurring simultaneously. The first step is stabilization of the 
depigmenting process and the second step involves residual follicular 
melanocytes stimulation. 
Immunomodulation 
 UV radiation has immunomodulating effects by stabilizing the abnormal 
immune response. Nuclear DNA is the major molecular target for UVB, with 
absorption by nucleotides leading to induction of various DNA photoproducts, 
such as pyrimidine dimers. NBUVB also induces isomerization of urocanic acid 
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from the trans to the cis form, which may be responsible for its 
immunomodulatory effects. In addition, NBUVB has been shown to induce 
immunosuppressive effects including induction of interleukin‑10, reduced 
natural killer cell activity, and lymphoproliferation.
[85]
 
Melanocyte migration from the outer hair root sheath 
 NBUVB stimulates the amelanotic melanocytes from the outer root sheath 
of hair follicle to proliferate and synthesis melanin. It also causes migration of 
melanocytes outward to adjacent vitiligo skin inducing perifollicular 
repigmentation. Subsequently these melanocytes migrate downward to the hair 
matrices to synthesis melanin.  
 Histopathologically and immunologically melanocyte precursors can be 
demonstrated on tissue samples after ultraviolet radiation therapy, that are 
capable of proliferation and migration into depigmented epidermis, to repopulate 
it with  new generations of melanocytes.
[86]
 
Vitamin D and Narrowband UVB 
 Calcium imbalance, Vitamin‑D receptor‑polymorphism, and low levels 
of circulating 25‑hydroxy Vitamin‑D has been implicated in the 
etiopathogenesis of vitiligo. Vitamin‑D modulates melanogenesis at cellular 
level by inducing tyrosinase enzyme and immature melanocytes in bulge region 
to produce melanin. Molecular studies have shown that patients receiving 
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NBUVB have shown an increase in the serum levels of 25-hydroxy Vitamin‑D 
indicating the role of Vitamin‑D in NBUVB‑induced repigmentation.[87] 
Basic fibroblast growth factor and Narrowband-UVB 
 Following NBUVB irradiation to vitiligo patches, basic fibroblast growth 
factor (bFGF) and endothelin‑1 (ET‑1) are released from keratinocytes, which 
induces melanocyte proliferation. NBUVB irradiation also stimulates the 
expression of focal adhesion kinase and matrix metalloproteinase‑2 (MMP‑2) in 
melanocytes. This leads to enhanced melanocyte migration and overcomes the 
deleterious effects of vitiligo associated IgG on cell migration, melanin 
formation, and tyrosinase expression.
[88]
 
Indications
[89]
 
 Narrow band UVB have been used in the treatment of various dermatosis. 
Narrow band UVB responsive dermatoses includes the following 
Common indications 
1. Vitiligo 
2. Psoriasis 
3. Atopic dermatitis 
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Other indications 
 Mycosis fungoides, Parapsoriasis, Generalized lichen planus, Pityriasis 
rosea, Pruritus, Seborrheic dermatitis, Pityriasis rubra pilaris, Scleroderma, 
Nummulardermatitis and Graft versus host disease 
Dosing Regimen
[90]
 
 NB-UVB dosing regimen is based on either the patients skin type or 
depending on MED (Minimal erythema dose). There are two regimens that are 
most commonly used; the first involves determination of the individual's 
minimum erythema dose (MED). First therapeutic dose is 70% of MED value. 
Treatment is given thrice weekly. Subsequent dose increments are 40, 20, 10% 
depending on skin tolerance. 
Step 1: 
 Determination of minimal erythema dose (MED)              Reading after 24 
hours 
Step 2: 
 Start of treatment  
 First therapeutic dose               70% of MED 
Step 3: 
 Treatment continuation thrice weekly 
 No erythema              Increase by 40% (30%) 
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Minimal erythema                Increase by 20% (10%) after every other treatment 
Persistent asymptomatic erythema              No increase 
Painful erythema with or without edema or blistering              No treatment till 
symptoms subsides. 
Step 4: 
Resumption of treatment    
After resolution of symptoms              Reduction of last dose by 50%, further 
increase by 10%. 
 The second method of dosing regimen comprises a standard starting dose 
of 250 mJ/cm
2
, with stepwise increase (usually 20%) based on the patient's 
erythema response. In the photodermatoses, dosing is used with caution with 
only 10% incremental regimen on sun-exposed sites.  In case of mild erythema, 
the irradiation dose is kept constant for succeeding treatments or until resolution 
of symptoms. The goal of therapy is to accomplish persistent asymptomatic 
erythema. In case of painful erythema “with or without edema/blistering”, further 
treatment is withdrawn till the symptoms subside. After resolution of symptoms, 
the dose can be administered 50% of the last dose and subsequent dose 
increments should be by 10%. 
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 If subsequent treatments with NB-UVB phototherapy are missed by 
patients for 
 4-7 days - Keep dose of exposure, the same previous dose 
 1-2 weeks - Decrease dose by 25% 
 2-3 weeks - Decrease dose by 50% or start over 
 3-4 weeks - Start over from initial first dose. 
Advantages of NB-UVB 
1. Safe  in pregnancy and children 
2. No need for post exposure eye protection 
3. Safe in patients with hepatic impairment 
4. Side effects are minimal 
Adverse effects 
 Erythema 
 Dryness of skin  
 Photoageing 
 Sunburn 
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VITILIGO TREATMENT RESPONSE ASSESSMENT 
 Many vitiligo treatments have been analyzed using nominal binary scales 
in which the ratio of treated patients who either do or do not attain a definite 
degree of repigmentation is reported and matched by nonparametric statistical 
methods. The degree of repigmentation that describes success as often been set 
somewhat indiscriminately at 50% to 75% repigmentation based mainly on the 
global impression of the overall response.  
 To allow an independent and consistent visual evaluation of results, a 
consensus regarding an adequate scoring system is essential. This standard 
scoring system will allow accurate and appropriate data collection that can be 
used both for direct comparisons.  
 Quantitative scales are used for evaluating treatment response in vitiligo. 
The primary advantage of using quantitative scales for evaluating vitiligo is that 
they provide direct estimates of the expected quantitative responses that patients 
might expect to achieve. In contrast, nominal and nonparametric methods can 
only estimate the proportion of patients who achieve a certain arbitrarily set level 
of response. Quantitative methods provide data that are generally more intuitive 
and meaningful to patients and physicians, while at the same time being more 
sensitive for detecting significant subtle treatment effects. Another benefit of 
using quantitative scales is that they can more definitely capture successive 
trends in response by time or treatment number. 
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 A simple quantitative scale to measure the response of treatment in 
patients with vitiligo is Vitiligo Area Scoring Index or VASI. 
 Hamzavi et al. introduced the VASI, which is a standardized, sensitive 
technique to measure the degree and percentage of de ⁄ repigmentation. In the 
VASI, the patient‟s body is divided into five distinct and mutually exclusive 
regions: the hands, upper extremities (other than the hands), trunk, lower 
extremities (other than the feet) and the feet. The axillary and inguinal regions 
are included in the upper and lower extremities, respectively, whereas the 
buttocks are included in the lower extremities. The face and neck areas can be 
evaluated separately. For each body region, the VASI is calculated as the product 
of the vitiligo area in hands units (set at 1% per unit) and the extent of 
depigmentation within each hand unit-measured patch estimated to the nearest of  
one of the following percentages: (0, 10%, 25%, 50%, 75%, 90% or 100%).
[91] 
 The VASI, applied to the whole body, is calculated using the below 
formula, which considers the contributions of all body regions                  
(possible range: 0–100): 
 Total body VASI    =         ∑       (hand units) x (depigmentation) 
                 (all body site) 
 
 By the end of therapy, the percentage reduction in VASI for each patient 
was assessed and correlated with physicians global assessments and patients 
global assessments separately. 
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AIM OF THE STUDY 
 
 The aim of the study is to compare the efficacy and tolerability of 
Narrowband-UVB alone versus Narrowband-UVB with 0.1% tacrolimus in the 
treatment of vitiligo. 
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MATERIALS AND METHODS 
 
Design of the study 
 Narrowband-UVB alone versus Narrowband-UVB with 0.1% tacrolimus 
in the treatment of vitiligo. 
 This is a randomized, open, prospective, comparative study conducted in 
vitiligo patients attending the vitiligo clinic in the Department of Dermatology, 
Chengalpattu Medical College Hospital, Chengalpattu over a period of 1 year. 
Period of study 
 The period of study was conducted from April 2015 to April 2016 (1year). 
Institutional ethical committee approval was obtained prior to the conduct of the 
study. 
Patients Selection   
 52 patients in the age group 15-60 years were enrolled in the study. 
Inclusion criteria   
 All patients of either sex  in the age group 15-60 years 
 Patients with body surface area involvement less than 20% 
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Exclusion criteria   
Before Study 
  Age less than 15 years and more than 60 years 
  Body surface area involvement more than 20% 
  History of photosensitivity 
 History of administration of drugs causing photosensitization 
 History of any treatment of vitiligo in preceding 3 months 
 Severe hepatic, renal and systemic skin disease. 
 Mucosal vitiligo 
During Study 
 If patient develops severe side effects/intolerant during treatment. 
 If patient wants to discontinue the treatment. 
 If patient uses any other medication (other than study medication and 
therapy) during the study period. 
 During the initial visit, patients demographic details including the name, 
age, sex, address, outpatient number were recorded.  
 A detailed clinical history was taken in all patients which includes the 
following  
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1. Time of onset of the disease  
2. Duration, course and progression of the disease were noted 
3. Presence or absence of any potential precipitating events including 
emotional stress and trauma were noted 
4. Presence or absence of any family history of vitiligo 
5. Occupational history of patients were noted 
6. History regarding photosensitivity and intake of drugs causing 
photosensitivity 
7. History of any previous treatment taken so far noted 
8. History of any associated diseases like diabetes mellitus, hypertension, 
thyroid disease, anaemia and other autoimmune diseases were recorded. 
 All patients were examined in good light. A detailed dermatological 
assessment of the disease was carried out which includes total number and 
distribution of lesions, size of lesions, site of involvement, total body surface area 
involved were noted. Presence of leucotrichia in the patch was also noted. Also 
details regarding skin texture, presence or absence of perifollicular pigmentation, 
Koebners phenomenon and systemic problems were all noted. Total duration of 
the disease were also noted. 
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 Relevant hematological and biochemical investigations like complete 
blood count, random blood sugar, blood urea, serum creatinine, liver function 
test, peripheral smear, urine analysis, thyroid profile were carried out in all 
patients. Patients were evaluated for cataract and retinal pathology by ophthalmic 
examination. 
 General and systemic examinations were carried out in all patients. 
 Estimation of percentage of body surface area that is affected by vitiligo 
was carried out by using rule of nine (Wallace) or Lund and Browder chart. 
 Rule of 9 (Wallace) includes 9% for head and neck (head 7%, neck 2%), 
9% for each upper limb (arm 4%, forearm 3%, hand 2%) 9% for the front of each 
lower limb (thigh 5%, leg 2.5%, foot1.5 %) and 9% for the back of each lower 
limb (thigh 5%, leg 2.5%, foot1.5 %). 9% for the front of chest, 9% for the front 
of the abdomen, 9% for the upper back, 9% for the lower back and 1% for the 
external genitalia.  
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Lund and Browder Chart 
Adult 
Anatomic Structure Surface area 
Anterior head 4.5% 
Posterior head 4.5% 
Anterior torso 18% 
Posterior torso 18% 
Anterior leg, each 9% 
Posterior leg, each 9% 
Anterior arm, each 4.5% 
Posterior arm, each 4.5% 
Genitalia/perineum 1% 
 
Adult, Obese >80 kg 
Anatomic structure Surface Area 
Head and neck 2% 
Anterior torso 25% 
Posterior torso 25% 
Leg, each 20% 
Arm, each 5% 
Genitalia/perineum 0% 
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 Initial photograph of the patients were taken before commencement of 
treatment and at each follow up and at the end of treatment. Patients preliminary 
reports were collected before start of the study. Patient was then randomly 
allocated into two groups 1 and 2 by means of sequentially numbered list. 
Patients in group 1 were treated with Narrowband-UVB alone and in group 2 
were treated with Narrowband-UVB with 0.1% tacrolimus. 
 Before starting therapy, all patients were counselled regarding the safety 
of therapy and written consent before initiation of therapy was obtained. The 
following treatment methodology was adopted during the study and treatment 
response assessed in both the groups. 
Treatment schedule 
 Narrowband-UVB therapy alone was given to patients allocated in         
group1. Whole body phototherapy chamber containing 6 feet 100W fluorescent 
bulbs of Philips TL-01, total of 36 bulbs, with an emission spectrum of 311nm 
were used. This chamber has integrated dosimetry and the time to deliver correct 
dose is automatically calculated. 
 Standard initial dose of 250 mj/cm
2 
was given to all patients in group 1 
treated with NB-UVB and subsequently irradiation dose was increased by 20% 
for every other treatment. Therapy was administered thrice weekly on Tuesday, 
Thursday and Saturday. Patient was instructed to shield their genitals and use UV 
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protective goggles for eye protection during exposure. Whole body irradiation 
was given barring these protected areas. 
 Patients in group 2 was treated with once daily topical application of 0.1% 
tacrolimus ointment at night together with concomitant Narrowband-UVB 
irradiation thrice weekly on Tuesday, Thursday and Saturday. The initial starting 
dose of Narrowband-UVB and subsequent dose increment were the same as 
described in group 1. Patient was instructed to shield their genitals and use UV 
protective goggles during each treatment session. 
 Patient was asked to report to the physician if any adverse reaction occurs. 
The development of any phototoxic erythema precludes further dose increments. 
In case of localized erythema, that part was shielded and incremental exposures 
were allowed to rest of the body. When generalized erythema occurred, then 
irradiation was stopped until resolution of erythema. After erythema resolved, the 
optimal constant dose of irradiation was held at previous dose. 
Assessment of therapy 
Treatment efficacy parameters 
1. VASI (Vitiligo Area Scoring Index) 
2. Physician global assessment 
3. Patient global assessment 
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 All the patients in both the groups were followed and assessed every 
fortnightly. Any macular repigmentation, shrinkage of lesion, development of 
new lesions, adverse reactions were noted. 
 Estimation of body surface area was initially assessed in both the groups. 
The total body was divided into following mutually exclusive regions: 
1. Face  
2. Hand  
3. Feet 
4. Upper limbs(excluding hands) 
5. Lower limbs(excluding feet) 
6. Trunk 
 Axilla was included in upper limb. Inguinal region and buttock was 
included in lower limb.  For each body region, vitiligo area scoring index was 
calculated by the following method.  One hand unit includes the palm plus the 
volar surface of all the digits. One hand unit is approximately equal to 1% of 
total body surface area. This was used as a guide to estimate the baseline 
percentage of vitiligo involved in any body area.  
 In order to eliminate variation in hand size, one hand unit is defined to be 
volar hand including the fingers of single investigator. The extent of  residual 
repigmentation within each vitiligo patch which has been present at the baseline 
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was estimated to the nearest of one of the following percentages: 0, 10%, 25%, 
50%, 75%, 90% or 100% during each follow up. Any new depigmented lesions 
when developed during the study was also included in VASI calculation.  
 Standardized assessment for estimating the degree of pigmentation to 
calculate the Vitiligo Area Scoring Index (VASI) is as follows: 
 At 100% depigmentation, no pigment is present 
 At 90%, specks of  pigmentation are present 
 At 75%, the depigmented area exceeds the pigmented area. 
 At 50%, the depigmented area and the pigmented area are equal 
 At 25%, the pigmented area exceeds the depigmented area 
 At 10%, only specks of depigmentation are present. 
 VASI for each body region is calculated by the product of the area of 
vitiligo in hand units (which was set at 1% per unit) and extent of depigmentation 
within each measured hand unit patch. 
 Total body VASI was then estimated by   
 Total Body VASI = ∑ [hand units] X [residual depigmentation] 
                                                
            All body sites    
 
 Percentage reduction in VASI in each body region of all patients were 
evaluated and correlated with Physician global assessment on a 5 point ordinal 
scale at the end of 12 months. 
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Physician global assessment 
Score improvement in percentage 
0. 0% - No Change 
1. 1-25% - Minimal improvement 
2. 26-50% - Definite improvement 
3. 51-75% - Marked improvement 
4. 76-100% - Excellent improvement 
 The subjective satisfaction of the patient is assessed by patients global 
assessment on the response to the treatment as perceived by the patient with or 
without comparison to previous treatment if any. Patients global assessment was 
assessed in a 4 point scale at the end of 12 months.  
Patient global assessment 
1. Much better 
2. Slightly better 
3. Same 
4. Worse 
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SYNOPSIS OF ANALYSIS 
 
 The primary efficacy parameter, VASI was assessed at baseline and then 
every 2 months during follow up for 1 year. The secondary efficacy parameters, 
1.Physician global assessment and 2.Patient global assessment were evaluated at 
the end of 12 months. 
 Group -1-Narrowband-UVB therapy  
 Group-2 –Narrowband-UVB with 0.1% tacrolimus  
 Number of patients in group 1 = 25. 
 Number of patients in group 2 = 25. 
 Total number of lesion areas involved in group1 = 32 areas in total. 
 Total number of lesion areas involved in group2 = 34 areas in total. 
 All the baseline and demographic analysis were done for 25 patients of 
each group .The VASI score, difference reduction were done for 66 lesion areas 
of the patients in total. The effectiveness of therapy between the two groups were 
analysed using Chi Square test for discrete variables.   
 The difference reduction of VASI initial (0 month) with last follow up 
VASI (12 months) were determined. The difference of test groups 1 & 2 were 
analysed using students „t‟ test. 
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 The VASI initial with all respective follow ups of each group were 
analysed separately. The mean difference reduction were obtained using paired 
„t‟ test. Using ANOVA (analysis of variance), the difference in reduction 
between VASI initial and final with respect to lesion area were analyzed. The 
statistical analysis were obtained with the assumption of α = level of significance 
= 95% confidence level. So  p < 0.05 is the cutoff value for statistical 
significance.  
Statistics used:  
1. „t‟ test  
2. Paired „t‟ test  
3. Chi square test  
4. ANOVA  
Software used:  
 SPSS (version 17). 
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OBSERVATIONS AND RESULTS 
 
 Out of 52 patients enrolled in the study, only 50 patients completed the 
study. One patient in each group discontinued from study, so they were excluded 
from analysis. 
 NB-UVB 
NB-UVB with 
0.1% tacrolimus 
Total 
Completed study 25 25 50 
Drop out 1 1 2 
Total 26 26 52 
 
In this prospective study comparing two types of vitiligo treatment, NB-
UVB was given to 25 patients having lesions in 32 areas totally and NB-UVB 
with topical 0.1 % tacrolimus was given to 25 patients having lesions in 34 areas 
in total. In both the groups, some patients have vitiligo lesions in more than one 
area. Hence total number of lesions vary in two groups. 
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Table 1- AGEWISE DISTRIBUTION 
 
 GROUP  
NB-UVB 
NB-UVB  
with 0.1% 
Tacrolimus 
Total 
AGE 
GROUP 
15 to 20 yrs Number of patients 6 6 12 
% within group 24.0% 24.0% 24.0% 
% of Total 12.0% 12.0% 24.0% 
21-25 yrs Number of patients 5 4 9 
% within group 20.0% 16.0% 18.0% 
% of Total 10.0% 8.0% 18.0% 
26-30 yrs Number of patients 5 6 11 
% within group 20.0% 24.0% 22.0% 
% of Total 10.0% 12.0% 22.0% 
31 -35 yrs Number of patients 5 3 8 
% within group 20.0% 12.0% 16.0% 
% of Total 10.0% 6.0% 16.0% 
36 yrs& 
above 
Number of patients 4 6 10 
% within group 16.0% 24.0% 20.0% 
% of Total 8.0% 12.0% 20.0% 
 Total Number of patients 25 25 50 
% within group 100.0% 100.0% 100.0% 
% of Total 50.0% 50.0% 100.0% 
 
Table 1 shows age wise distribution of patients treated with NB-UVB 
alone and NB-UVB with tacrolimus. Age distribution in both the groups was in 
the range of 15-60 years. In the above table, age distribution between the two 
groups of treatment, x
2
 = 1.102 and p = 0.771. There is no significance difference 
between the age distributions in both the groups. 
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Chart showing age distribution 
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Table 2 - SEXWISE DISTRIBUTION 
 
 GROUP  
NB-UVB 
NB-UVB 
with 0.1% 
Tacrolimus 
Total 
SEX Female Number of patients 13 14 27 
% within group 52.0% 56.0% 54.0% 
% of Total 26.0% 28.0% 54.0% 
Male Number of patients 12 11 23 
% within group 48.0% 44.0% 46.0% 
% of Total 24.0% 22.0% 46.0% 
 Total Number of patients 25 25 50 
% within group 100.0% 100.0% 100.0% 
% of Total 50.0% 50.0% 100.0% 
Table 2 shows the sex distribution of patients treated with NB-UVB alone 
and NB-UVB with tacrolimus. Out of 25 patients treated with NB-UVB alone, 
13 were females and 12 were males. In 25 patients treated with NB-UVB and 
tacrolimus, 14 were females and 11 were male patients. In the above table, 
distribution of sex ratio between the two groups of treatment, x
2
 = 0.081 and p = 
0.777. Hence it is not statistically significant.  
Chart showing gender distribution 
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Table 3 - DISEASE DURATION DISTRIBUTION 
 NB-UVB 
NB-UVB with 
0.1% Tacrolimus 
Total 
Duration of 
disease 
(in months) 
6 
months 
Number of patients 2 1 3 
% within group 8.0% 4.0% 6.0% 
% of Total 4.0% 2.0% 6.0% 
12 
months 
Number of patients 13 15 28 
% within group 52.0% 60.0% 56.0% 
% of Total 26.0% 30.0% 56.0% 
24 
months 
Number of patients 7 6 13 
% within group 28.0% 24.0% 26.0% 
% of Total 14.0% 12.0% 26.0% 
36 
months 
Number of patients 3 3 6 
% within group 12.0% 12.0% 12.0% 
% of Total 6.0% 6.0% 12.0% 
 Total Number of patients 25 25 50 
% within group 100.0% 100.0% 100.0% 
% of Total 50.0% 50.0% 100.0% 
 
Table 4 - MEAN DURATION OF DISEASE IN MONTH 
Duration Of Disease N Mean Std. Deviation 
Std. Error 
Mean 
NB-UVB 25 17.76 9.080 1.816 
NB-UVB with 0.1% 
tacrolimus 
25 17.52 8.818 1.764 
 
Table 3 shows the distribution of duration of disease in patients treated 
with NB-UVB alone and NB-UVB with tacrolimus. The mean duration of 
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disease in NB-UVB alone group was 17.76 months and NB-UVB with 
tacrolimus group was 17.52 months as shown in table 4.   
 
 
 
Chart showing Disease duration distribution 
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Table 5 - DISEASE ASSOCIATION DISTRIBUTION 
 NB-UVB NB-UVB with 
0.1% Tacrolimus 
Total 
Associated 
Disease 
No 
Number of patients 23 25 48 
% within group 92.0% 100.0% 96.0% 
% of Total 46.0% 50.0% 96.0% 
Yes 
Number of patients 2 0 2 
% within group 8.0% .0% 4.0% 
% of Total 4.0% .0% 4.0% 
Total 
Number of patients 25 25 50 
% within group 100.0% 100.0% 100.0% 
% of Total 50.0% 50.0% 100.0% 
 
 Table 5 shows the distribution of associated other diseases in patients 
treated with NB-UVB alone and NB-UVB with tacrolimus. 2 patients had 
associated disease in NB-UVB treated group, while none of the patients had 
associated disease in NB-UVB with tacrolimus group.  
Chart showing Disease association distribution 
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Table 6 - VITILIGO AREA DISTRIBUTION 
 NB-UVB 
NB-UVB with 
0.1%  
Tacrolimus 
Total 
Face 
Number of lesion area 4 4 8 
% within group 12.5% 11.8% 12.1% 
% of Total 6.1% 6.1% 12.1% 
Feet 
Number of lesion area 3 3 6 
% within group 9.4% 8.8% 9.1% 
% of Total 4.5% 4.5% 9.1% 
Hand 
Number of lesion area 2 3 5 
% within group 6.3% 8.8% 7.6% 
% of Total 3.0% 4.5% 7.6% 
Lower limb 
Number of lesion area 8 8 16 
% within group 25.0% 23.5% 24.2% 
% of Total 12.1% 12.1% 24.2% 
Trunk 
Number of lesion area 8 8 16 
% within group 25.0% 23.5% 24.2% 
% of Total 12.1% 12.1% 24.2% 
Upper limb 
Number of lesion area 7 8 15 
% within group 21.9% 23.5% 22.7% 
% of Total 10.6% 12.1% 22.7% 
Total 
Number of lesion area 32 34 66 
% within group 100.0% 100.0% 100.0% 
% of Total 48.5% 51.5% 100.0% 
 
 Table 6 shows the distribution of percentage of lesion areas in patients 
treated with NB-UVB alone and NB-UVB with tacrolimus. The percentage 
distribution of lesion area was maximum in trunk, lower limb and upper limb in 
both the groups. 
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Chart showing Vitiligo area distribution 
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Table 7- BODY SURFACE AREA DISTRIBUTION 
Body Surface Area 
Number of Patients 
Total 
NB-UVB 
NB-UVB with 0.1%  
Tacrolimus 
1-5% 4 4 8 
6-10% 16 13 29 
11-15% 4 7 11 
16-20% 1 1 2 
Total 25 25 50 
 
 Table 7 shows the distribution of vitiligo in body surface area (BSA) in 
patients treated with NB-UVB alone and NB-UVB with tacrolimus. In both the 
groups, maximum number of patients had vitiligo involving 6-10% of total body 
surface area. 
Chart showing Body surface area distribution 
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Table 8 - AREAWISE MEAN VASI DISTRIBUTION IN NB-UVB 
 
95% Confidence 
Interval for Mean 
  
N Mean 
Std. 
Deviation 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
VASI 
0 month 
Face 4 1.125 .3227 .1614 .611 1.639 
Feet 3 1.083 .3819 .2205 .135 2.032 
Hand 2 .625 .1768 .1250 -.963 2.213 
Lower limb 8 2.594 .8231 .2910 1.906 3.282 
Trunk 8 3.625 1.0774 .3809 2.724 4.526 
Upper limb 7 2.250 .5774 .2182 1.716 2.784 
Total 32 2.328 1.2156 .2149 1.890 2.766 
V ASI 
2 month 
Face 4 1.125 .3227 .1614 .611 1.639 
Feet 3 1.083 .3819 .2205 .135 2.032 
Hand 2 .625 .1768 .1250 -.963 2.213 
Lower limb 8 2.594 .8231 .2910 1.906 3.282 
Trunk 8 3.625 1.0774 .3809 2.724 4.526 
Upper limb 7 2.250 .5774 .2182 1.716 2.784 
Total 32 2.328 1.2156 .2149 1.890 2.766 
VASI 
4 month 
Face 4 1.063 .3146 .1573 .562 1.563 
Feet 3 1.083 .3819 .2205 .135 2.032 
Hand 2 .625 .1768 .1250 -.963 2.213 
Lower limb 8 2.488 .9380 .3316 1.703 3.272 
Trunk 8 3.531 .9769 .3454 2.715 4.348 
Upper limb 7 2.150 .6258 .2365 1.571 2.729 
Total 32 2.248 1.1977 .2117 1.817 2.680 
VASI 
6 month 
Face 4 .750 .5000 .2500 -.046 1.546 
Feet 3 1.083 .3819 .2205 .135 2.032 
Hand 2 .575 .2475 .1750 -1.649 2.799 
Lower limb 8 2.313 .8210 .2903 1.626 2.999 
Trunk 8 3.188 1.0753 .3802 2.289 4.086 
Upper limb 7 2.007 .5711 .2159 1.479 2.535 
66 
 
 
95% Confidence 
Interval for Mean 
  
N Mean 
Std. 
Deviation 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Total 32 2.045 1.1458 .2026 1.632 2.458 
VASI 
8 month 
Face 4 .54 .325 .163 .02 1.05 
Feet 3 .97 .257 .148 .33 1.60 
Hand 2 .50 .354 .250 -2.68 3.68 
Lower limb 8 2.16 .896 .317 1.41 2.91 
Trunk 8 2.97 1.039 .367 2.10 3.84 
Upper limb 7 1.79 .636 .240 1.20 2.37 
Total 32 1.86 1.134 .200 1.45 2.27 
VASI 
10month 
 
Face 4 .4125 .23585 .11792 .0372 .7878 
Feet 3 .9667 .25658 .14814 .3293 1.6040 
Hand 2 .5000 .35355 .25000 -2.6766 3.6766 
Lower limb 8 1.9688 .89080 .31495 1.2240 2.7135 
Trunk 8 2.9375 1.05009 .37126 2.0596 3.8154 
Upper limb 7 1.6786 .64087 .24223 1.0859 2.2713 
Total 32 1.7672 1.13554 .20074 1.3578 2.1766 
VASI 
12 month 
Face 4 .38750 .262599 .131300 -.03035 .80535 
Feet 3 .96667 .256580 .148137 .32929 1.60405 
Hand 2 .50000 .353553 .250000 -2.67655 3.67655 
Lower limb 8 1.93750 .842509 .297872 1.23314 2.64186 
Trunk 8 2.84375 1.156793 .408988 1.87665 3.81085 
Upper limb 7 1.51429 .556563 .210361 .99955 2.02902 
Total 32 1.69688 1.124503 .198786 1.29145 2.10230 
 
 Table 8 shows the distribution of mean vitiligo area scoring index (VASI) 
in face, feet, hand, lower limb, trunk and upper limb before treatment and during  
2 months, 4 months, 6 months, 8 months, 10 months, 12 months follow up period 
in patients treated with NB-UVB alone. Only after 4 months follow up, mean 
VASI started reducing in face, lower limb, trunk and upper limb, but feet and 
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hand areas not shown reduction in VASI. Mean VASI started to reduce at 6 
months of treatment in hand lesions and at 8 months in feet lesions. 
                            
 
Graph showing comparison of Mean VASI reduction in NB-UVB 
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Table 9 - AREAWISE MEAN VASI DISTRIBUTION IN NB-UVB WITH      
0.1% TACROLIMUS 
 
 
95% Confidence 
Interval for Mean 
 
 N Mean 
Std. 
Deviation 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
VASI  
0 month 
Face 4 1.50000 .456435 .228218 .77371 2.22629 
Feet 3 .75000 .250000 .144338 .12897 1.37103 
Hand 3 .66667 .288675 .166667 -.05044 1.38378 
Lower limb 8 2.50000 .640870 .226582 1.96422 3.03578 
Trunk 8 3.00000 .779194 .275487 2.34858 3.65142 
Upper limb 8 2.36875 .897591 .317346 1.61835 3.11915 
Total 34 2.15294 1.029779 .176606 1.79363 2.51225 
VASI  
2 month 
Face 4 1.37500 .661438 .330719 .32250 2.42750 
Feet 3 .75000 .250000 .144338 .12897 1.37103 
Hand 3 .66667 .288675 .166667 -.05044 1.38378 
Lower limb 8 2.46875 .589150 .208296 1.97621 2.96129 
Trunk 8 2.91875 .711607 .251591 2.32383 3.51367 
Upper limb 8 2.33125 .899975 .318189 1.57885 3.08365 
Total 34 2.10294 1.012942 .173718 1.74951 2.45637 
VASI  
4 month 
Face 4 1.12500 .478714 .239357 .36326 1.88674 
Feet 3 .71667 .202073 .116667 .21469 1.21864 
Hand 3 .58333 .381881 .220479 -.36531 1.53198 
Lower limb 8 2.26875 .659511 .233173 1.71738 2.82012 
Trunk 8 2.76250 .702928 .248522 2.17484 3.35016 
Upper limb 8 2.14375 .876860 .310017 1.41068 2.87682 
Total 34 1.93529 .988152 .169467 1.59051 2.28008 
VASI  
6 month 
Face 4 .75000 .353553 .176777 .18742 1.31258 
Feet 3 .68333 .256580 .148137 .04595 1.32071 
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Hand 3 .53333 .351188 .202759 -.33907 1.40573 
Lower limb 8 2.06250 .593867 .209964 1.56601 2.55899 
Trunk 8 2.62500 .654654 .231455 2.07770 3.17230 
Upper limb 8 2.01250 .822344 .290743 1.32500 2.70000 
Total 34 1.77206 .957442 .164200 1.43799 2.10613 
VASI  
8 month 
Face 4 .65625 .373260 .186630 .06231 1.25019 
Feet 3 .63333 .251661 .145297 .00817 1.25849 
Hand 3 .45000 .390512 .225462 -.52009 1.42009 
Lower limb 8 1.84375 .625892 .221286 1.32049 2.36701 
Trunk 8 2.35938 .771818 .272879 1.71412 3.00463 
Upper limb 8 1.81250 .810093 .286411 1.13525 2.48975 
Total 34 1.58824 .923335 .158351 1.26607 1.91040 
VASI  
10 month 
Face 4 .51550 .434313 .217156 -.17559 1.20659 
Feet 3 .56667 .288675 .166667 -.15044 1.28378 
Hand 3 .41667 .332916 .192209 -.41034 1.24368 
Lower limb 8 1.62500 .566947 .200446 1.15102 2.09898 
Trunk 8 2.07813 .752785 .266150 1.44878 2.70747 
Upper limb 8 1.65625 .766922 .271148 1.01509 2.29741 
Total 34 1.40844 .852953 .146280 1.11083 1.70605 
VASI  
12 month 
Face 4 .45300 .351429 .175715 -.10620 1.01220 
Feet 3 .53333 .230940 .133333 -.04035 1.10702 
Hand 3 .41667 .332916 .192209 -.41034 1.24368 
Lower limb 8 1.53125 .646936 .228727 .99040 2.07210 
Trunk 8 1.67188 .850256 .300611 .96104 2.38271 
Upper limb 8 1.46875 .836527 .295757 .76940 2.16810 
Total 34 1.23638 .819935 .140618 .95029 1.52247 
 
 Table 9 shows the mean vitiligo area scoring index (VASI) before starting 
treatment and follow up during 2 months, 4 months, 6 months, 8 months, 10 
months and 12 months in different lesion areas treated with NB-UVB and 
tacrolimus. On observing the results, face, lower limb, trunk and upper limb 
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shows reduction in mean VASI from 2 month follow up but feet and hand areas 
shows reduction in mean VASI only from 4 months follow up. 
  
                                         
Graph showing comparison of Mean VASI reduction in NB-UVB and 
tacrolimus 
 
 
 
 On observing table 8 and table 9, NB-UVB and tacrolimus shows 
reduction in mean VASI earlier than NB-UVB alone during follow up. Lesions in 
feet and hand needs longer duration of treatment than in other areas in both 
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modalities of treatment but NB-UVB with tacrolimus shows earlier response than 
NB-UVB alone in these areas. 
 
 
 
Table 10- AREAWISE MEAN VASI DIFFERENCE IN NB-UVB 
  
95% Confidence 
Interval for Mean 
 N 
VASI-Mean 
Difference 
Std. 
Deviation 
Std. Error 
Lower 
Bound 
Upper 
Bound 
Face 4 .73750 .188746 .094373 .43716 1.03784 
Feet 3 .11667 .125831 .072648 -.19591 .42925 
Hand 2 .12500 .176777 .125000 -1.46328 1.71328 
Lower limb 8 .65625 .129387 .045745 .54808 .76442 
Trunk 8 .78125 .160217 .056645 .64730 .91520 
Upper limb 7 .73571 .118019 .044607 .62656 .84486 
Total 32 .63125 .264194 .046703 .53600 .72650 
 
 Table 10 shows distribution of different lesion areas and mean VASI 
difference between initial and 12 months after treatment with NB-UVB alone. 
Table 11 -TOTAL MEAN VASI DIFFERENCE IN NB-UVB 
 Sum of Squares df Mean Square F Sig. 
Between Groups 1.614 5 .323 15.248 .000 
Within Groups .550 26 .021   
Total 2.164 31    
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 Table 11 shows the mean values of difference between VASI before 
treatment and VASI in final follow up among lesions in different parts of the 
body were analysed by ANOVA (Analysis of Variance). The F test was used. 
The P value is 0.000 (<0.05, 95% confidence interval). This clearly indicates that 
there exists a statistical significance between mean levels of difference values 
among different body areas from the onset of disease. 
Table 12 - POST HOC TESTS  
Multiple comparisons between Mean VASI difference of various areas in 
NB-UVB 
 
(I) area (J) area 
 
95% Confidence 
Interval 
Mean Difference 
(I-J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
Face 
Feet .620833
*
 .111108 .000 .39245 .84922 
Hand .612500
*
 .125985 .000 .35353 .87147 
Lowerlimb .081250 .089085 .370 -.10187 .26437 
Trunk -.043750 .089085 .627 -.22687 .13937 
Upper limb .001786 .091181 .985 -.18564 .18921 
Feet 
Face -.620833
*
 .111108 .000 -.84922 -.39245 
Hand -.008333 .132800 .950 -.28131 .26464 
Lowerlimb -.539583
*
 .098487 .000 -.74203 -.33714 
Trunk -.664583
*
 .098487 .000 -.86703 -.46214 
Upper limb -.619048
*
 .100387 .000 -.82540 -.41270 
Hand 
Face -.612500
*
 .125985 .000 -.87147 -.35353 
Feet .008333 .132800 .950 -.26464 .28131 
Lowerlimb -.531250
*
 .115008 .000 -.76765 -.29485 
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Trunk -.656250
*
 .115008 .000 -.89265 -.41985 
Upper limb -.610714
*
 .116640 .000 -.85047 -.37096 
Lower 
Limb 
Face -.081250 .089085 .370 -.26437 .10187 
Feet .539583
*
 .098487 .000 .33714 .74203 
Hand .531250
*
 .115008 .000 .29485 .76765 
Trunk -.125000 .072738 .098 -.27451 .02451 
Upper limb -.079464 .075291 .301 -.23423 .07530 
Trunk 
Face .043750 .089085 .627 -.13937 .22687 
Feet .664583
*
 .098487 .000 .46214 .86703 
Hand .656250
*
 .115008 .000 .41985 .89265 
Lower limb .125000 .072738 .098 -.02451 .27451 
Upper limb .045536 .075291 .551 -.10923 .20030 
Upper 
limb 
Face -.001786 .091181 .985 -.18921 .18564 
Feet .619048
*
 .100387 .000 .41270 .82540 
Hand .610714
*
 .116640 .000 .37096 .85047 
Lower limb .079464 .075291 .301 -.07530 .23423 
Trunk -.045536 .075291 .551 -.20030 .10923 
 
 Table 12 shows the distribution results of post hoc multiple comparison 
tests, in lesions at various parts of body in patients treated with NB-UVB alone. 
This test compares the mean VASI difference between lesions in various areas 
which revealed, lesions in face, lower limb, trunk and upper limb were uniformly 
reduced with treatment and not statistically significant but while comparing 
lesions in these areas with hand and feet, the reduction was statistically 
significant (p<0.05). This was shown in table 12. 
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Table 13 - AREAWISE MEAN VASI DIFFERENCE IN NB-UVB WITH 
TACROLIMUS 
  
95% Confidence Interval 
for Mean 
 N Mean 
Std. 
Deviation 
Std. Error 
Lower 
Bound 
Upper 
Bound 
Face 4 1.04700 .138453 .069227 .82669 1.26731 
Feet 3 .21667 .125831 .072648 -.09591 .52925 
Hand 3 .25000 .050000 .028868 .12579 .37421 
Lower limb 8 1.00000 .188982 .066815 .84201 1.15799 
Trunk 8 1.32813 .517280 .182886 .89567 1.76058 
Upper limb 8 .90000 .165292 .058440 .76181 1.03819 
Total 34 .92391 .450257 .077218 .76681 1.08101 
 
 Table 13 shows distribution of different lesion areas and mean VASI 
difference between initial and 12 months after treatment with NB-UVB and 
tacrolimus.  
Table 14 TOTAL MEAN VASI DIFFERENCE IN NB-UVB WITH 
TACROLIMUS 
 
 
Sum of Squares df Mean Square F Sig. 
Between Groups 4.282 5 .856 9.955 .000 
Within Groups 2.408 28 .086   
Total 6.690 33    
 Table 14 shows the mean values of difference between VASI before 
treatment and VASI in final follow up among lesions in different parts of the 
body were analysed by ANOVA. The F test was used. The P value is 0.000 
(P<0.05, 95% confidence interval). This indicates that there is a statistical 
significance between mean level of difference values among different body areas 
from onset of disease in patients treated with NB-UVB and tacrolimus. 
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Table 15 - POST HOC TEST 
Multiple Comparisons between Mean VASI difference of various areas 
in NB-UVB with tacrolimus 
(I) area (J) area 
 
95% Confidence 
Interval 
Mean 
Difference (I-J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
Face Feet .830333
*
 .224001 .001 .37149 1.28918 
Hand .797000
*
 .224001 .001 .33815 1.25585 
Lower limb .047000 .179600 .795 -.32089 .41489 
Trunk -.281125 .179600 .129 -.64902 .08677 
Upper limb .147000 .179600 .420 -.22089 .51489 
Feet Face -.830333
*
 .224001 .001 -1.28918 -.37149 
Hand -.033333 .239467 .890 -.52386 .45719 
Lower limb -.783333
*
 .198556 .000 -1.19006 -.37661 
Trunk -1.111458
*
 .198556 .000 -1.51818 -.70474 
Upper limb -.683333
*
 .198556 .002 -1.09006 -.27661 
Hand Face -.797000
*
 .224001 .001 -1.25585 -.33815 
Feet .033333 .239467 .890 -.45719 .52386 
Lowerlimb -.750000
*
 .198556 .001 -1.15672 -.34328 
Trunk -1.078125
*
 .198556 .000 -1.48485 -.67140 
Upper limb -.650000
*
 .198556 .003 -1.05672 -.24328 
Lower 
limb 
Face -.047000 .179600 .795 -.41489 .32089 
Feet .783333
*
 .198556 .000 .37661 1.19006 
Hand .750000
*
 .198556 .001 .34328 1.15672 
Trunk -.328125
*
 .146643 .033 -.62851 -.02774 
Upper limb .100000 .146643 .501 -.20038 .40038 
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Trunk Face .281125 .179600 .129 -.08677 .64902 
Feet 1.111458
*
 .198556 .000 .70474 1.51818 
Hand 1.078125
*
 .198556 .000 .67140 1.48485 
Lower limb .328125
*
 .146643 .033 .02774 .62851 
Upper limb .428125
*
 .146643 .007 .12774 .72851 
Upper 
limb 
Face -.147000 .179600 .420 -.51489 .22089 
Feet .683333
*
 .198556 .002 .27661 1.09006 
Hand .650000
*
 .198556 .003 .24328 1.05672 
Lower limb -.100000 .146643 .501 -.40038 .20038 
Trunk -.428125
*
 .146643 .007 -.72851 -.12774 
 
 Table 15 shows the distribution results of post hoc multiple comparison 
test in treatment with NB-UVB and tacrolimus, in lesions at various parts of 
body. This table shows, the results of comparing mean VASI difference between 
various parts of body which revealed lesions in face, lower limb, trunk and upper 
limb were uniformly reduced with treatment and not statistically significant. But 
while comparing lesions in these areas with hands and feet, the reduction was 
statistically significant (p < 0.05). 
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Table 16 -  PAIRED SAMPLE STATISTICS OF MEAN VASI IN NB-UVB 
 Mean N 
Std. 
Deviation 
Std. Error 
Mean 
t P 
VASI 0month 2.32813
a
 32 1.215554 .214882 
0 0 
VASI 2month 2.32813
a
 32 1.215554 .214882 
VASI 0month 2.32813 32 1.215554 .214882 
3.500 .001 
VASI 4month 2.24844 32 1.197678 .211722 
VASI 0month 2.32813 32 1.215554 .214882 
7.080 .000 
VASI 6month 2.04531 32 1.145845 .202559 
VASI 0month 2.32813 32 1.215554 .214882 
10.543 .000 
VASI 8month 1.86094 32 1.133631 .200399 
VASI 0month 2.32813 32 1.215554 .214882 
12.942 .000 
VASI 10month 1.76719 32 1.135541 .200737 
VASI 0month 2.32813 32 1.215554 .214882 
13.516 .000 
VASI 12month 1.69688 32 1.124503 .198786 
 Table 16 shows the paired sample statistics of mean VASI before 
treatment and follow up after 2 months, 4 months, 6 months, 8 months, 10 
months, 12 months in NB-UVB alone treatment group. This table shows the 
reduction in mean VASI only from 4 months of follow up and progressive 
reduction during follow up period. In paired T test, there is a statistically 
significant improvement in mean VASI reduction from before treatment to 4 
months follow up, before treatment to 6 months follow up, before treatment to 8 
months follow up, before treatment to 10 months  and before treatment to 12 
months follow up. 
78 
 
Table 17 - PAIRED SAMPLE STATISTICS OF MEAN VASI IN NB-UVB 
WITH TACROLIMUS 
 Mean N 
Std. 
Deviation 
Std. Error 
Mean 
t P 
VASI 0month 2.15294 34 1.029779 .176606 
2.209 .034 
VASI 2month 2.10294 34 1.012942 .173718 
VASI 0month 2.15294 34 1.029779 .176606 
9.881 .000 
VASI 4month 1.93529 34 .988152 .169467 
VASI 0month 2.15294 34 1.029779 .176606 
9.195 .000 
VASI 6month 1.77206 34 .957442 .164200 
VASI 0month 2.15294 34 1.029779 .176606 
11.388 .000 
VASI 8month 1.58824 34 .923335 .158351 
VASI 0month 2.15294 34 1.029779 .176606 
11.675 .000 
VASI 10month 1.40844 34 .852953 .146280 
VASI 0month 2.15294 34 1.029779 .176606 
11.850 .000 
VASI 12month 1.23638 34 .819935 .140618 
 
 Table 17 shows the paired sample statistics of mean VASI before 
treatment and follow up after 2 months, 4 months, 6 months, 8 months, 10 
months and 12 months in NB-UVB with tacrolimus treatment group. This table 
shows the reduction in mean VASI from 2 months of follow up and progressive 
reduction during follow up period. 
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In paired T test, there is a statistically significant improvement for treatment from 
before treatment to 2 months follow up, before treatment to 4 months follow up, 
before treatment to 6 months follow up, before treatment to 8 month, before 
treatment to 10 months follow up and before treatment to 12 months follow up. 
On observing the results of table 16 and 17,  response to treatment was earlier at 
2 months follow up in NB-UVB with tacrolimus than NB-UVB alone which 
shows response to treatment only from 4th month follow up. 
 
Table 18  -  COMPARISON OF MEAN VASI REDUCTION BETWEEN 
TWO GROUPS  
Group Statistics 
 Group N 
Mean VASI 
Reduction 
Std. 
Deviation 
Std. Error 
Mean 
Difference NB-UVB 32 .631250 .2641938 .0467033 
NB-UVB WITH 
0.1% Tacrolimus 
34 .923912 .4502568 .0772184 
 
Table 19  - Independent Samples Test 
 
  
Levene's Test for 
Equality of Variances 
t-test for Equality of 
Means 
  F Sig. t Df 
Difference Equal variances 
assumed 
4.086 .047 -3.195 64 
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Levene's Test for 
Equality of Variances 
t-test for Equality of 
Means 
  F Sig. t Df 
Difference Equal variances 
assumed 
4.086 .047 -3.195 64 
Equal variances 
not assumed 
  
-3.243 53.884 
 
Table 20- Independent Samples Test 
  t-test for Equality of Means 
  Sig. (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
Difference Equal variances 
assumed 
.002 -.2926618 .0916082 
Equal variances not 
assumed 
.002 -.2926618 .0902435 
 
 Table 18, 19, 20 shows the combined analysis of difference in 
reduction of mean VASI scores between treatment with NB-UVB alone and NB-
UVB with tacrolimus. On observing the study results, mean VASI reduction in 
NB-UVB treated group was 0.631 and in NB-UVB with tacrolimus group was 
0.923, t = -3.195, p = 0.002 which shows there is statistically significant 
reduction in mean VASI scores in treatment with NB-UVB and tacrolimus than 
NB-UVB alone.                                       
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Table 21- COMPARISON OF PERCENTAGE OF REDUCTION IN      
MEAN VASI BETWEEN TWO GROUPS 
Group Statistics 
 
Group N 
Mean 
VASI 
Std. 
Deviation 
Std. Error 
Mean 
%of  Reduction NB-UVB 32 31.390142 19.5579352 3.4573872 
NB-UVB with 
0.1% Tacrolimus 
34 45.340894 18.0666609 3.0984068 
 
Table 22  
                                             Independent Samples Test 
  
Levene's Test for 
Equality of Variances 
t-test for Equality 
of Means 
  F Sig. t Df 
% of 
Reduction 
Equal variances 
assumed 
.041 .841 -3.012 64 
Equal variances not 
assumed 
  
-3.005 62.761 
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Table 23  
 Independent Samples Test 
  t-test for Equality of Means 
  Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
% of Reduction Equal variances 
assumed 
.004 -13.9507523 4.6312955 
Equal variances not 
assumed 
.004 -13.9507523 4.6425909 
 
 Table 21, table 22 and table 23 shows the final combined analysis of 
treatment results between NB-UVB alone group and NB-UVB with tacrolimus 
group. In this study, the total percentage of reduction in mean VASI was 31% in 
NB-UVB treated group and 45% in NB-UVB and tacrolimus group, t = -3.012,       
p = 0.004 (<0.05). There is statistically significant percentage of reduction in 
mean VASI in NB-UVB with tacrolimus group than NB-UVB alone group.  
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Table 24 - SIDE EFFECTS DISTRIBUTION 
 
 NB-UVB 
NB-UVB with 
0.1% 
Tacrolimus 
Total 
Side 
Effect 
No 
Number of patients 22 23 45 
% within group 88.0% 92.0% 90.0% 
% of Total 44.0% 46.0% 90.0% 
Yes 
Number of patients 3 2 5 
% within group 12.0% 8.0% 10.0% 
% of Total 6.0% 4.0% 10.0% 
 Total 
Number of patients 25 25 50 
% within group 100.0% 100.0% 100.0% 
% of Total 50.0% 50.0% 100.0% 
 
Table 24 shows the distribution of side effects in patients treated with  
NB-UVB alone and NB-UVB with tacrolimus. Out of 25 patients treated with 
NB-UVB, 3 patients had side effects. Similarly in 25 patients treated with  
NB-UVB and tacrolimus, 2 patients had side effects due to treatment.  
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Chart showing Side effect distribution 
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Table 25 Total reduction in VASI: Physician’s Global assessment 
 
Narrowband 
UVB 
Narrowband UVB 
with 0.1% 
Tacrolimus 
Score Comment % Number of 
patients 
% Number of  
patients 
% 
0 No  Change 0% 2 8 0 0 
1 Minimal 
improvement 
1-25% 9 36 4 16 
2 Definite 
improvement 
26-50% 11 44 13 52 
3 Marked 
improvement 
51-75% 3 12 6 24 
4 Excellent 
improvement 
75-100% 0 0 2 8 
 
 Table 25 shows the distribution of physician global assessment score in 
patients treated with NB-UVB alone and NB-UVB with tacrolimus. In the 
present study, vitiligo area scoring index (VASI) was used to assess the 
treatment.  
 Minimal improvement in total VASI reduction was seen in 36% of 
patients treated with  NB-UVB and 16% of patients treated with NB-UVB and 
tacrolimus. Definite improvement was seen only in 44% of patients treated with 
NB-UVB, while 52% of patients treated with NB-UVB and tacrolimus showed 
definite improvement. Only 12% of patients treated with NB-UVB showed 
marked improvement, while 24% of patients treated with NB-UVB and 
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tacrolimus showed marked improvement. Excellent improvement was seen only 
in patients of NB-UVB with tacrolimus treated group.  
 
 
Chart showing physician global assessment 
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Table 26 - Patient global assessment score 
 Narrowband UVB 
Narrowband UVB with 
0.1% Tacrolimus 
Score Comment 
Number of 
patients 
% 
Number of 
patients 
% 
1 Much better 8 32 11 44 
2 Slightly better 15 60 14 56 
3 Same 2 8 0 0 
4 Worse 0 0 0 0 
 
 Table 26 shows the distribution of patient global assessment score in 
patients treated with NB-UVB alone and NB-UVB with tacrolimus. Out of 25 
patients treated with NB-UVB, only 32% had much better improvement whereas 
44% of patients treated with NB-UVB and tacrolimus showed much better 
improvement. 60% of patients treated with NB-UVB and 56% of patients treated 
with NB-UVB and tacrolimus showed slightly better improvement. 2% in NB-
UVB group showed no change in treatment response.  
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Chart showing Patients global assessment 
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DISCUSSION 
 
 Vitiligo is an acquired pigmentation disorder, characterized by 
depigmented patches, as a result of disappearance of functioning melanocytes 
from the epidermis. This condition, cosmetically disfiguring especially in dark-
skinned individuals, makes the lesional skin more sensitive to sunburns. It affects 
0.1-2% of the world‟s population, irrespective of gender and race.[92] 
 Only few studies are available comparing the efficacy and tolerability of 
NB-UVB with NB-UVB and tacrolimus. This is one such study.  
 The current study was conducted to present a mode of treatment which 
might be beneficial to the patients of vitiligo. The baseline demographic data and 
baseline characteristics in both the study groups when compared were similar. In 
the present study, the mean duration of disease in NB-UVB alone group was 
17.76 months and NB-UVB with tacrolimus group was 17.52 months. Sex ratio 
between two arms of treatment was similar but not statistically significant. In this 
study, two patients had associated disease in NB-UVB treated group while others 
showed no disease association.  
 In our study NB-UVB with tacrolimus shows statistically significant 
reduction in mean VASI. In a similar study conducted by Hs Satyanarayan et 
al
[93]
 at Chandigarh in 25 patients revealed repigmentation was slightly better in 
lesions treated with NB-UVB and tacrolimus than NB-UVB alone but overall 
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difference was not statistically significant. In a similar comparative study
[94]
 
conducted at Pakistan revealed NB-UVB with tacrolimus was superior to  
NB-UVB alone in repigmentation of vitiligo which was comparable to our study 
results. 
 A recent study by Nordal et al.
[95]
 assessed the additive effect of 
tacrolimus ointment (0.1%) once daily in vitiligo patients treated with NB-UVB 
and concluded that the combination of NB-UVB and tacrolimus ointment (0.1%) 
was more effective than NB-UVB treatment alone for vitiligo. This was similar 
to our study which shows a statistically significant difference in VASI reduction 
after treating with NB-UVB and tacrolimus than NB-UVB alone. 
 The overall efficacy of NB-UVB with 0.1% tacrolimus was greater than 
NB-UVB alone after 12 months of treatment, with earlier treatment response in 
NB-UVB and tacrolimus group in our study. 
 In our study vitiligo area assessed by VASI shows statistically significant 
reduction with NB-UVB and tacrolimus than NB-UVB alone. Similar results 
were noted by a study conducted by Majid et al
[96]
 which showed the effect of 
combining topical tacrolimus and NB-UVB therapy in inducing repigmentation 
in vitiligo lesions and concluded that addition of topical tacrolimus increases the 
extent of overall repigmentation achieved with NB-UVB therapy in vitiligo. 
 Fai et al.
[97]
 evaluated the efficacy and tolerability of combined treatment 
with NB-UVB and topical tacrolimus in vitiligo. Their study had shown 
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repigmentation was evident on more than 70% of lesions and grade of 
repigmentation was dependent on the site, with lesions over face, trunk and limbs 
showing better outcome while the therapeutic effect on the extremities and 
genital areas were quite disappointing. These results were comparable as in our 
study also, lesions on face, trunk and limb showed better and earlier clinical 
response while hand and feet lesions take longer duration of treatment for clinical 
response  in tacrolimus with NB-UVB group. But the above mentioned study was 
not a comparative trial as ours. 
 A comparative study conducted by Mehrabi D et al.
[98]
 revealed better 
repigmentation in treatment with NB-UVB and tacrolimus than NB-UVB alone 
but the difference was not statistically significant. In our study, reduction in 
vitiligo with repigmentation assessed with VASI shows statistically significant 
improvement in NB-UVB with tacrolimus. 
 Side effects were minimal in both groups, and no patients stopped 
treatment because of side effects in both groups. 
 
 
 
     
 
92 
 
CONCLUSION 
 
 Narrow band-UVB with tacrolimus treatment is superior to Narrow band-
UVB alone for treatment of vitiligo in terms of reduction in vitiligo area which 
was comparable with similar studies. There was a statistically significant 
reduction in percentage of VASI with NB-UVB and tacrolimus group when 
compared to NB-UVB alone at the end of treatment. 
 Narrow band-UVB with tacrolimus shows earlier repigmentation than 
narrow band UVB alone in vitiligo, like previous published studies. 
 Lesions in the face, trunk, upperlimbs, and lowerlimbs shows earlier 
repigmentation in patients treated with NB-UVB and tacrolimus than NB-UVB 
alone. 
 Lesions in hands and feet needs longer duration of treatment while 
comparing trunk, face, upper and lower limbs in both modalities of treatment.  
 The results of secondary efficacy parameters like physician global 
assessment, patient global assessment were in favour of NB-UVB and tacrolimus 
group.  
 No severe side effects were noted. Only patients showed transient 
erythema, burning and itching in both the groups. 
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GROUP 1 - NB-UVB PRE TREATMENT 
 
 
 
POST TREATMENT 
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 GROUP 1 - NB-UVB PRE TREATMENT  
 
 
POST TREATMENT 
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GROUP 1 - NB-UVB   PRE TREATMENT 
 
 
 
POST TREATMENT 
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GROUP 1 - NB-UVB PRE TREATMENT 
 
 
 
POST TREATMENT 
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GROUP 2 - NB-UVB WITH 0.1% TACROLIMUS 
PRE TREATMENT 
 
 
 
POST TREATMENT 
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GROUP 2 - NB-UVB WITH 0.1% TACROLIMUS 
PRE TREATMENT 
 
 
 
POST TREATMENT 
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GROUP 2 - NB-UVB WITH 0.1% TACROLIMUS 
PRE TREATMENT 
 
 
POST TREATMENT 
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GROUP 2 - NB-UVB WITH 0.1% TACROLIMUS 
PRE TREATMENT 
 
 
POST TREATMENT 
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ABBREVIATIONS 
 
NB-UVB  –  Narrow Band Ultra Violet B 
MAO  –  Monoamine oxidase 
ROS  –  Reactive Oxygen Species 
H2O2  –  Hydrogen Peroxide 
bFGF  –  Basic Fibroblast Growth Factor  
NSV  –  Non - Segmental Vitiligo 
OMP  –  Oral Minipulse Therapy 
UVR  –  Ultra Violet Radiation 
PUVA  –  Psolaren and Ultra Violet A 
MOP  –  Methoxy psoralen 
SPF  –  Sun Protection Factor 
UVB  –  Ultra Violet B 
UVA  –  Ultra Violet A 
NFAT  –  Nuclear Factor of Activated T cells 
KD  –  Kilodalton 
TNFα  –  Tumour Necrosis Factor 
IFNγ  –  Interferon gamma 
IL  –  Interleukin  
BSA  –  Body Surface Area 
VASI  –  Vitiligo Area Scoring Index 
 
 
 
113 
 
 
PROFORMA 
 
 
 
Name:                                             Address           : 
Age    :                                            Marital status   :     
Sex     :                                            Occupation      : 
Case no:                                          Hospital no       : 
Date: 
Present complaints:   
Duration 
Onset and Progression 
History of  itching 
History of  previous treatment 
History of  photosensitivity 
Past history 
 
Associated diseases 
DM/HT/Thyroid disease/Anemia/Other Auto immune disease 
Personal history 
Family history  
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General Examination:  
 1. Built       5. Icterus 
 2. Height     6. Cyanosis 
 3. Weight                7. Clubbing 
 4. Pallor               8. Lymphadenopathy 
 Vital signs:  PR      BP    RR  
Systemic Examination:  
 CVS     RS    ABD   CNS 
Dermatological Examination: 
 Area of Involvement: Face/trunk/upper limb/lower limb/hand/feet  
 Total body surface area in percentage 
 Photograph 
Investigations:  
 Complete Blood count 
 Platelet count  
 Peripheral smear  
 Blood Sugar 
  Blood Urea  
 Serum creatinine  
 Liver Function Test  
 Thyroid profile and anti-thyroid antibodies 
 Urine routine 
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NB-UVB / NB-UVB with 0.1% tacrolimus 
(baseline / follow up) 
S.No Date Dose 
Cumulative 
Dose 
Follow up & 
Remarks 
Adverse Events 
1              
 2              
 3              
 4              
 5              
 6              
 7              
 8              
 9              
 10              
 11              
 12              
 13              
 14              
 15              
 16              
 17              
 18              
 19              
 20              
 21              
 22              
 23              
 24              
 25              
 26              
 27              
 28              
 29              
 30              
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Weekly Treatment Response: 
(NB-UVB/NB-UVB with tacrolimus) 
 
S.No. Weeks Face Trunk Upper limb Lower limb Hand Feet Mean 
 0        
 2        
 4        
 6        
 8        
 10        
 12        
 14        
 16        
 18        
 20        
 22        
 24        
 26        
 28        
 30        
 32        
 34        
 36        
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ADVERSE EFFECTS 
 
Adverse 
Events 
Severity Onset Course Action 
Relationship to 
study therapy 
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KEY TO MASTER CHART 
 
 
VASI    –  Vitiligo Area Scoring Index 
 
PHY. GA   -  Physician global assessment 
 
PATIENTS GA  -  Patients global assessment 
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MASTER CHART 
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